Indrayani Biotech Limited's board of directors concluded their meeting on April 9, 2026, with significant decisions regarding corporate restructuring and governance appointments. The meeting, which was previously scheduled and announced on April 6, 2026, addressed key strategic initiatives for the company's future growth.

Board Meeting Outcomes

The board meeting, held from 4:45 PM to 5:50 PM on April 9, 2026, resulted in two major decisions that will shape the company's operational structure and compliance framework.

Demerger Evaluation and Restructuring Committee

The board has given preliminary approval to explore the demerger of the company's food division into a separate entity. This strategic decision aims to unlock shareholder value through focused business operations and enhanced operational efficiency.

To oversee this complex process, the board has constituted a dedicated "Restructuring Committee" with comprehensive authority to manage all aspects of the demerger evaluation. The committee has been empowered to make necessary decisions and initiate required actions throughout the restructuring process.

Internal Auditor Appointment

In a separate governance decision, the board approved the appointment of M/S VAITHIANATHAN & ASSOCIATES, Chartered Accountants, as the company's Internal Auditor. This appointment covers an extended period of two financial years, demonstrating the company's commitment to robust internal audit processes.

Regulatory Compliance

The board meeting outcome was filed under Regulation 30 of SEBI (LODR) Regulations, 2015, ensuring proper disclosure of material events to stakeholders. The regulatory filing was executed by Ramya Ravi, Company Secretary and Compliance Officer, maintaining the company's commitment to transparent corporate governance practices.

These strategic decisions reflect Indrayani Biotech's focus on optimizing its business structure while strengthening internal governance mechanisms for sustainable growth.

Indrayani Biotech Limited has issued a clarification to BSE Limited regarding recent share price movement following a surveillance inquiry. The company responded to BSE's communication dated April 8, 2026, providing detailed explanation for the observed price volatility in its scrip.

Recent Corporate Intimations Drive Market Activity

The company attributes the share price movement to market reaction following two significant intimations made on April 6, 2026:

Both meetings were scheduled to take place on April 9, 2026, the same date as the company's clarification to the exchange.

Regulatory Compliance and Disclosure

Indrayani Biotech emphasized its commitment to transparent disclosure practices under SEBI regulations. The company stated it has been consistently disclosing all material events, information, and announcements that may impact operations or performance, including price-sensitive information as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

No Undisclosed Material Information

The company clarified that beyond the aforementioned disclosures, there is no undisclosed information or pending announcements that could influence price or volume behavior in the scrip. Management confirmed the share price movement is purely market-driven and emphasized that no material information remains undisclosed to the stock exchange.

Potential Business Restructuring

The Board Meeting scheduled for April 9, 2026, was specifically convened to discuss the proposal for a potential demerger of the company's food business into a separate entity. This strategic consideration represents a significant corporate development that could reshape the company's business structure and operations.

The clarification was signed by Ramya Ravi, Company Secretary and Compliance Officer, reaffirming the company's commitment to maintaining compliance with all listing regulations in letter and spirit.